publications
Home >
주요실적

주요실적

  3. 2023
  4. Yang DW, Son KB (corresponding author). Impact of the COVID-19 Pandemic on the Public Perceptions of the Roles and Functions of Community Pharmacies in South Korea: Updated Cross-Sectional Self-Reported Web-Based Survey. JMIR Public Health Surveill (SSCI) 9:e46723. 2023.
  5. Kim BK, Son KB (corresponding author). Tightened Social Distancing Measures and Increased Violence during the COVID-19 Pandemic in South Korea. Frontiers in Psychology (SSCI). 14. 2023.
  6. Son KB. Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system? Frontiers in Public Health (SSCI). 11. 2023. 

  8. 2022
  9. Son KB. Patenting and patent challenges in South Korea after introducing a patent linkage system. Globalization and Health (SSCI). 18(95). 2022. 
  10. Son KB. Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market? Frontiers in Public Health (SSCI). 10. 2022. 
  11. Son KB. Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures. Expert Review of Pharmacoeconomics & Outcomes Research (SSCI). 22(5):815-822. 2022. 
  12. Son KB, Lee EK, Lee SW. Understanding patient and physician responses to various cost-sharing programs for prescription drugs in South Korea: A multilevel analysis. Frontiers in Public Health (SSCI). 10. 2022. 
  13. Son KB, Park S. Perceptions of Regulatory Decision-Making for New Drugs From the Viewpoints of the Manufacturers in South Korea. Frontiers in medicine (SCIE), 9. 2022
  14. Son KB. The impact of COVID-19 on the number of active small primary care businesses by severity of the pandemic: evidence from South Korea. BMC primary care (SCIE), 23(1), 1-8. 2022
  15. Choi NH, Son KB (corresponding author), Byun J. et al. Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea. Globalization and Health (SSCI). 18(34). 2022.
  16. Son KB, Lee EK. Importance of a usual source of care in choosing low-priced generic drugs: a cross-sectional study. Family practice (SCIE). 172. 2022.

  18. 2021
  19. Son KB, Lee TJ, Hwang SS. Disease severity classification and COVID-19 outcomes, Republic of Korea. Bulletin of the World Health Organization (SCIE). 99(1):62-66. 2021.
  20. Son KB, Choi NH, Lee B, Byun J, Yang DW, Lee TJ. Patent challenges in the era of the patent linkage system: Recent evidence from South Korea after the Korea United States Free Trade Agreement. Globalization and Health (SSCI). 17(116). 2021.
  21. Son KB. Market exclusivity of the originator drugs in South Korea: A retrospective cohort study. Frontiers in Public Health (SSCI). 9(264). 2021.
  22. Son KB, Park S, You MS. Manufacturers’ perceptions of the decision-making process for new drug reimbursement in South Korea. International Journal of Technology Assessment in Health Care (SCIE). 37(1), E88, 2021.

  24. 2020
  25. Son KB. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis. Globalization and Health (SSCI). 16(98). 2020.
  26. Kim BK, Son KB (corresponding author). Factors affecting the self-rated health of immigrant women married to native men and raising children in South Korea: a cross-sectional study. BMC Women’s Health (SSCI). 20(210). 2020.
  27. Son KB. Is greater generic competition also linked to lower drug prices in South Korea? Health Economics Review (SSCI). 10(30). 2020.
  28. Son KB. The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea. BMC Public Health (SCIE). 20(797). 2020.
  29. Son KB. Trends in the utilization of sodium hyaluronate eye drops, including disposable and multiuse forms, in South Korea: a 14-year longitudinal retrospective cohort study. Frontiers in Pharmacology (SCIE). 11(720). 2020.
  30. Son KB. Generic atorvastatin and rosuvastatin in the South Korean market: time of introduction in relation to manufacturer characteristics. Expert Review of Pharmacoeconomics & Outcomes Research (SSCI). 20(5). 2020.
  31. Son KB. Recent trends in tablet subdivision and factors affecting subdivision in South Korea: a cross sectional study. Medicine (SCIE). 99(18). 2020.
  32. Park JW, Bae SJ, Lee TJ, Son KB (corresponding author). Marketing and pricing strategies of blockbuster drugs in the South Korean market: a 15-year retrospective cohort study for choline alfoscerate. Frontiers in Pharmacology (SCIE). 11(232). 2020.
  33. Son KB. Do free trade agreements matter to drug lag? Recent evidence from Korea after the Korea-U.S. Free Trade Agreement. International Journal of Health Services (SSCI). 50(2):147-155. 2020.

  35. 2019
  36. Son KB. Importance of the Intellectual Property System in Attempting Compulsory Licensing of Pharmaceuticals: A Cross-sectional Analysis. Globalization and Health (SSCI). 15(42). 2019.
  37. Son KB, Choi SM, Kim DW. Public perceptions of the roles and functions of community pharmacies in the era of expanding scopes of pharmaceutical practice. Health and Social Care in the Community (SSCI). 27(4):1195-1201. 2019.
  38. Son KB, Bae SJ. Patterns of statin utilization for new users and market dynamics in South Korea: A 13-year Retrospective Cohort Study. BMJ Open (SCIE). 9(e026603). 2019.
  39. Son KB, Bae SJ, Lee TJ. Does the patent linkage system prolong effective market exclusivity? Recent evidence from the Korea-U.S. Free Trade Agreement in the Korean Market. International Journal of Health Services (SSCI). 49(2):306-321. 2019.
  40. Son KB, Kim CY, Lee TJ. Understanding of for Whom, Under What Conditions and How Compulsory Licensing of Pharmaceuticals Works in Brazil and Thailand: a Realist Synthesis. Global Public Health (SSCI). 14(1):122-134. 2019.
  41. Son KB. How much time before attempting compulsory licensing of pharmaceuticals? A non-parametric event history model with P-splines. International Journal of Health Services (SSCI). 49(1):68-84. 2019.

  43. 2018
  44. Son KB. Understanding the adoption of new drugs decided by several stakeholders in the South Korean market: a nonparametric event history analysis. Health Economics Review (SSCI). 8(31). 2018.
  45. Son KB. Establishing Healthy Pharmaceutical Regulations on Statutory Exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States. Journal of Generic Medicines. 14(4): 167-174. 2018.
  46. Son KB, Ruth Lopert, Deborah Gleeson, Lee TJ. Moderating the Impact of Patent Linkage on Access to Medicines: Lessons from Variations in South Korea, Australia, Canada, and the United States. Globalization and Health (SSCI). 14(1): 101. 2018.
  47. Son KB, Lee TJ. Compulsory licensing of pharmaceuticals reconsidered: Current situation and its implication on access to medicines. Global Public Health (SSCI). 13(10):1430-1440. 2018.
  48. Son KB, Lee TJ. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs. Global Public Health (SSCI). 13(9):1169-1178. 2018.
PC버전 보기
관련사이트 바로가기
15588 경기도 안산시 상록구 한양대학로 55 한양대학교 약학대학(402호)TEL. 031-400-5812 E-mail. sonkyungbok@hanyang.ac.kr

Copyright (c) 2016 Hanyang University. All Rights Reserved.

TOP
 
사이트맵 닫기